[已阅读次]
喻志强

姓名:喻志强
职称:教授,博士生导师
联系邮箱: yuzq@smu.edu.cn
联系电话:020-61647250

学习经历:
1995.09-1999.07 湖南师范大学, 化学化工学院,学士
1999.09-2002.07 湖南师范大学, 生物化学,硕士
2007.10-2010.09 长崎大学药学院,机能性分子化学,博士

工作经历:
2002.07-2005.10 中国科学技术大学生命科学学院   助教
2005.10-2006.09 深圳康哲药业有限责任公司  多肽研发员
2006.10-2007.09 长崎大学药学院,机能性分子化学  访学学者
2011.01-2015.07 美国亚利桑那州立大学生物设计院, 博士后(Research Fellow)
2015.07-至今 南方医科大学药学院教授

研究方向:
1. 多肽结构和功能,多肽微球缓释制剂研究;
2. 多肽自组装及其在生物医学中运用(载药,组织工程);
3. 新型纳米靶向递送系统研究;
4. 中药纳米制剂研究

主要学术任职:
1.
Pharmacognosy Magazine Drug Design,Development and Therapy杂志编委;   2. 担任ACS Nano, Chem SciChem. Comm, Nanoscale, J. Mater. Chem. B, ACS Appl. Mater. Interfaces, Acta Biomater, Theranostics, Sci. Rep, Mol. PharmBioconjugate. ChemEur J Med Chem, BMC, BMCLJ. Agr. Food ChemFood Chem, Analyst, Anal Biochem等药剂学,生物材料,药物化学和分析等领域40多个国际刊物的审稿人;  3. 国家自然科学基金评审专家:  4. 国家博士后特别自然基金评审专家;5. 浙江省自然科学基金评审专家;6. 中国生物医药技术纳米生物技术分会委员; 7. 中国抗癌协会纳米肿瘤学专业委员会第一届青年委员会成员; 8. 中国药剂学专业委员会青年委员会成员;9. 中国化学快报编委会委员; 10. 广东省自然医学研究会-干细胞与中医再生医学专业委员会第一届委员会常委委员


主要科研课题:
1. 南方医科大学高层次人才引进科研项目(C1032509) 项目负责人 靶向多肽或小分子糖基介导的多功能靶向给药系统的构建及其抗癌作用机制的研究 2016,01-2018,12  

2. 国家自然科学基金面上项目(81541086)  目负责人 基于细胞表面和线粒体双重靶向的阿霉素新型载药体系构建及肿瘤耐药逆转的研究 2016,01-2016,12  

3. 国家自然科学基金面上项目(81773642) 项目负责人 多层次双细胞器靶向的新型顺铂载药体系构建及耐药研究(2018,01-2021,12  

4. 广东省粤港联合创新基金(2017A050506016) 共同项目主持人 光控纳米颗粒诱发细胞自噬及其在肿瘤靶向治疗中的应用研究  (2017,01-2019,12)

5. 湖南大学化学生物传感与计量学国家重点实验室开放基金,项目主持人 二糖分子介导的多功能靶向纳米载药系统的构建及其抗肿瘤机制研究 (2017,01-2019,12)

6. 南方医科大学创新推动培育项目 项目负责人 多层靶向的新型顺铂素载药体系构建及耐药研究(2017,09-2019,8                                            

7. 四川大学高分子材料工程国家重点实验室开放基金,项目主持人 高分子铂前药载药体系及抗顺铂耐药研究 (2018,09-2020,08)

8. 高分子材料工程国家重点实验室(长春)科学基金课题  项目主持人   高分子铂前药载药体系及抗顺铂耐药研究  (2018,10-2021,09)                      

承担课程
《药剂学》《药物制剂设计学》 《药物制剂工程》

最近5年代表性论文

喻志强,博士,教授,博士生导师,先进生物材料PI团队主任。2010年长崎大学药学院获药学博士, 2011年1月起在美国亚利桑那州立大学从事博士后研究,开展博来霉素肿瘤药物的作用机制和靶向纳米给药系统的研究。2015年7月受聘于南方医科大学药学院生物药剂学科教授。 主要从事新型靶向纳米递药系统,中药纳米制剂研发。最近5年在J. Am. Chem. Soc, Advanced Sciences等国际期刊发表SCI论文40余篇,一作或通讯作者发表30余篇2015年来南方医发表20余篇),其中4篇ESI高引用论文, 获美国发明专利1项。2013年发表在J. Am. Chem. Soc论文关于博来霉素肿瘤药物研究成果被著名生物医学评论网站F1000专题报道,至今被国内外同行引用了220余次(google scholar)。论文总引用大约1400多次,H因子22。作为负责人主持8项科研基金,包括2项国家自然科学基金面上项目,广东省粤港合作创新基金等。担任ACS Nano, Chem Sci, Biomaterials, Theronostics等40多个国际主流杂志评审专家;国家和浙江省自然科学基金评审专家;中国抗癌协会纳米肿瘤学专业委员会第一届青年委员会成员;中国化学快报编委会委员; 广东省自然医学研究会-干细胞与中医再生医学专业委员会第一届委员会常委委员。

[1] Chen Q#, Yu M#et al., Ding J *,Yu Z*. Cisplatin-Crosslinked Hyaluronate-Doxorubicin Nanoparticles for Visualized and Targeted Chemotherapy of Multidrug-Resistant Breast Cancer, submitted

[2] Liao G#, Chen Q#, et al., Wang X*,Yu Z*. Lipopholic platinum(IV) drug delivery for combating cancer resistance, submitting to JMCB

[3] Peng Wu#, Xuefeng Wang#, Zigui Wang, Wen Ma, Jianjun Chen, Zhiqiang Yu*, Jizhen Li*, Dongfang Zhou*, Light-Activatable Prodrug and AIEgen Copolymer Nanoparticle for In Situ Dual-Drug Tracking and Combination Therapy,ACS Appl Mater Interfaces.in revise

[4] Yongbing Sun, Wen Ma, Yuanyuan Yang, Lei Bai, Aimin Li*, Zhiqiang Yu*Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy, Asian Journal of Pharmaceutical Sciences, in press

[5] Shuangjiao Sun, Qingwen Guan, Bin Wei,Yao Liu*, Yuanyuan Yang, Zhiqiang Yu* Highly luminescence manganese doped carbon dotsChinese Chemical Letters, in revise

[6] Falian Zhu, Lulu Cai, Jiaojiao Bai, Guozhu Tan, Yaodong Jiang, Zhiqiang Yu*, Shuwen Liu*and Fei Ren* Tumor-targeted and dual drug loaded gold nanorods for stimuli-responsive and combinational photothermal-chemotherapy, submitted to Biomater Sci, under review

[7] Yang Y#, Chen Q#, et al., Yu Z. Recent advance in polymer based microspheric systems for controlled protein and peptide delivery, Current Medicinal Chemistry, 2018, Just accepted

[8] Jiaming Hu, Yan Sheng*, Junfeng Shi, Bohao Yu, Zhiqiang Yu, Guochao Liao*.Long Circulating Polymeric Nanoparticles for Gene/Drug Delivery, Current Drug Metabolism,2018,19(9), 723-738.

[9] Wang P, Cheng J, Liu CC, Tang K, Xu F, Yu Z, Yu B, Chang J.The Development of New Small-Molecule Inhibitors Targeting Bacterial Metallo-β-lactamases.Curr Top Med Chem. 2018;18(10):834-843

[10] Jianing Zhang, Si Chen, Yue Ma, Dongyuan Wang, Jian Zhang, Yanding Wang, Wenjun Li, Zhiqiang Yu, Han Zhang, Feng Yin and Zigang LiOrganosilicon modification to enhance the stability of black phosphorus nanosheets under ambient conditionsJ. Mater. Chem. B, 2018,6, 4065-4070.

[11] Zhou Chen*, Cao Wu, Zhenfeng Zhang, Wangping Wu, Xuefeng Wang* and Zhiqiang Yu* Synthesis, functionalization, and nanomedical applications of functional magnetic nanoparticles, Chinese Chemical Letters, 20182911),1601-1608.

[12] Zhu F, Tan G, Jiang Y, Yu Z*, Ren F*, Rational design of multi-stimuli-responsive gold nanorod-curcumin conjugates for chemo-photothermal synergistic cancer therapy. Biomater Sci. 2018, 6, 2905-2917.

[13] Hou MLu X, Zhang Z, Xia Q, Yan C, Yu Z, Xu Y, Liu R. Conjugated Polymer Containing Organic Radical for Optical/MR Dual-Modality Bioimaging. ACS Appl Mater Interfaces. 2017 Dec 27;9(51):44316-44323.

[14] Xia Q, Chen Z, Yu Z, Wang L, Qu J, Liu R. Aggregation-Induced Emission-Active Near-Infrared Fluorescent Organic Nanoparticles for Noninvasive Long-Term Monitoring of Tumor Growth. ACS Appl Mater Interfaces 2018 May 23;10(20):17081-17088

[15] Zhang Y, Wang F, Li M, Yu Z, Qi R, Ding J, Zhang Z, Chen X. Self-Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma.

Adv Sci (Weinh). 2018,5(5):1700821

[16] S Chang, X Zhao, S Li, T Liao, J Long, Z Yu*, Y Cao*Cytotoxicity, cytokine release and ER stress-autophagy gene expression in endothelial cells and alveolar-endothelial co-culture exposed to pristine and carboxylated multiEcotoxicology and environmental safety, 2018, 161, 569-577.

[17] Yang, Y#, Chen, Q#, Ma, W, Yao, G, Cai, Z, Zhao, P, Yu, Z*. iRGD-Mediated and Enzyme-Induced Precise Targeting and Retention of Gold Nanoparticles for the Enhanced Imaging and Treatment of Breast Cancer. J Biomed Nanotechnol, 2018,14(8):1396-1408. IF=5.019

[18] Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X*, Yu Z*Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance. Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X*, Yu Z*. Chem Commun (Camb). 201854(42):5369-5372

[19] Hongmei Li, Xuefeng Wang, Zheng Cai, Ling Lu, Jia Tao, Bin Sun, Yuanyuan Yang, Quan Xu, Zhiqiang Yu*, Peng Zhao*, Ratiometric fluorescent biosensing of copper ion based on chromaticity change strategy, Anal Bioanal Chem. 2017,409(28):6655-6662

[20] Yuanyuan Yang, XuefengWang, GuochaoLiao, XiqiangLiu, Qiling Chen, Hongmei Li, Ling Lu, Peng Zhao*, ZhiqiangYu* iRGD-decorated red shift emissive carbon nanodots for tumor targeting fluorescence imaging, Journal of Colloid and Interface Science, 2017, 509:515-521

[21] Liu Y, Kim YJ, Siriwon N, Rohrs JA, Yu Z*, Wang P*.Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature. Biotechnol Bioeng. 2018 Jun;115(6):1403-1415

[22] Lijiang Wang†, Qiling Chen†, Jiaping Wu, Jianqin Wan, Liqian Zhou, Zhiqiang Yu,* and Hangxiang Wang*, Rationally Designing and Self-Emulsifying Hydrophobic Prodrug Conjugate that Enables Oral Co-Administration and Programmable Release of Dual Anticancer Therapeutic Drugs, J Biomed Nanotechnol, 2017, 13,1-12.

[23] Peng Zhao,† Quan Xu,† Jia Tao, Zongwen Jin,Yue Pan, Changmin Yu* and Zhiqiang Yu*, Near infrared quantum dots in biomedical applications: current status and future perspective, WIREs Nanomed Nanobiotechnol, 2017, e1483. doi: 10.1002/wnan.1483.

[24] Ong YS, Gao L*, Kalesh KA, Yu Z*, Wang J, Liu C, Li Y, Sun H, Lee SS*, Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications, Curr Top Med Chem. 2017;17(20):2302-2318.

[25] Liao Z, Chen L, Fu J, Sreenivasan ST, Yu Z* Ren J*, Biosynthesis and Characterization of Walnut Peptides-Zinc Complex and Its Antiproliferative Ability on Human Breast Carcinoma Cells through Induction of Apoptosis, J. Agr. Food Chem, 2016, 64(7):1509-1519.
[26] Yu Z, Cai Z, Chen Q, Liu M, Ye L, Ren J, Liao W *, S. Liu*, Engineering β-sheets peptide assemblies for biomedical applications, Biomaterials Science 2016, 4(3):365-74.
[27] Liao W, Zhang R, Dong C, Yu Z*, Ren J*, Novel Walnut Peptide–Selenium Hybrids with Enhanced Anticancer Synergism: Facile synthesis and mechanistic investigation of anticancer activity. Int J Nanomedicine 2016,11:1305-21
[28] Kuang T, Liu Y, Gong T, Peng X, Hu X*, Yu Z*. Enzyme-responsive nanoparticles for anti-cancer drug delivery. Curr Nanosci. 2016, 12 (1), 38-46.
[29]Gao L#, Yu Z#, Dan M, Fang Z, Yong SO, Miao P*, Lee SS*, Wen L*. Analogue of melanotan II (MTII): a novel melanotropin with super potent action on frog skin. Protein Pept Lett. 2015, 22, 762-766.

[30] Yu Z, Xu Q, Dong C, Lee SS, Gao L*, Li Y, Ortenzio MD, Wu J*. Self-assembling peptide nanofibrous hydrogel as a versatile drug delivery platform. Curr. Pharm. Des. 2015, 21, 4342-4354.
[31] Yu Z, Yan B, Gao L, Dong C, Zhong J, Hu X*, Liang F,* Targeted delivery of Bleomycin: a comprehensive anticancer review. Curr Cancer Drug Tar.2016;16(6):509-21

[32] Q Xu, T Kuang, Y Liu, L Cai, X Peng, TS Sreeprasad, P Zhao, Z Yu, N Li,Heteroatom-doped carbon dots: synthesis, characterization, properties, photoluminescence mechanism and biological applications, Journal of Materials Chemistry B2016, 4 (45), 7204-7219
[33] Xu Q*, Lv Y, Dong C, Sreeprased TS, Tian A, Zhang H, Tang Y, Yu Z*, Li N *. Three-dimensional micro/nanoscale architectures: fabrication and applications. Nanoscale, 2015, 7, 10883-10895.
[34] Yu Z, Paul R, Bhattacharya C, Bozeman TC, Rishel MJ, Hecht SM*. Structural features facilitating tumor cell targeting and internalization by Bleomycin and its disaccharide, Biochemistry. 2015; 54 (19):3100-3109.
[35] Yu B#, Yu Z#, Qi P, Yu D*, Liu H*. Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges. Eur. J. Med. Chem, 2015, 95, 35-40.
[36] Miao P*, Wang B, Yu Z*, Zhao J, Tang Y. Ultrasensitive electrochemical detection of microRNA with star trigon structure and endonuclease mediated signal amplification. Biosens Bioelectron , 2015, 63, 365–370.
[37] Schroeder BR, Ghare MI, Bhattacharya C, Paul R, Yu Z, Zaleski PA, Bozeman TC, Rishel MJ, Hecht SM*. The disaccharide moiety of Bleomycin facilitates uptake by cancer cells, J. Am. Chem. Soc, 2014, 136, 13641-13656.
[38] Madathil MM, Bhattacharya C, Yu Z, Paul R, Rishel MJ, Hecht SM*. Modified bleomycin disaccharides exhibiting improved tumor cell targeting. Biochemistry. 2014, 53(43):6800-10.
[39] Bhattacharya C, Yu Z, Rishel MJ, Hecht SM*. The Carbamoylmannose Moiety of Bleomycin Mediates Selective Tumor Cell Targeting. Biochemistry, 2014, 53 (20), 3264–3266.
[40] Yu Z, Li J, Zhu J, Zhu M, Jiang F, Zhang J, Li Z, Zhong M, Kaye JB, Du J*, Shen B*. A synthetic fourth transmembrane segment derived from TRPV4 channel self-assembles into a potassium channel to regulate the vascular smooth muscle cell membrane potential, J. Mater. Chem. B, 2014, 2, 3809-3818.
[41] Yu Z*,Yu B, Kaye JB, Tang C, Chen S, Dong C, Shen B*. Perspectives and Challenges of Cell Penetrating Peptides in Effective siRNA Delivery. Nano Life. 2014, 04, 1441016.
[42] Fu CY*, Xia RL, Zhang TF, Lu Y, Zhang SF, Yu ZQ*, Jin T, Mou XZ*. Hemokinin-1(4-11)-induced analgesia selectively up-regulates δ-opioid receptor expression in mice, PloS one, 2014, 9 (2): e90446.
[43] Yu Z, Schmaltz RM, Bozeman TC, Paul R, Rishel MJ, Tsosie KS, Hecht SM*. Selective tumor cell targeting by the disaccharide moiety of Bleomycin. J. Am. Chem. Soc, 2013, 135, 2883−2886.


下一条:朱秋华